Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  LJUBLJANA STOCK EXCHANGE, INC.  >  Krka d.d. Novo Mesto    KRKG   SI0031102120

KRKA D.D. NOVO MESTO (KRKG)
Mes dernières consult.
Most popular
Report
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2017 1 257 M
EBIT 2017 189 M
Net income 2017 151 M
Finance 2017 138 M
Yield 2017 5,12%
Sales 2018 1 304 M
EBIT 2018 194 M
Net income 2018 168 M
Finance 2018 109 M
Yield 2018 5,38%
P/E ratio 2017 11,83
P/E ratio 2018 10,64
EV / Sales2017 1,31x
EV / Sales2018 1,29x
Capitalization 1 787 M
More Financials
Company
KRKA dd is a generic pharmaceutical company, which engages in the development, production, marketing, and sale of human and animal health products.It offers prescription pharmaceuticals and non-prescription products.The company was founded by Boris Andrijanic in 1954 and is headquartered in Novo... 
Sector
Pharmaceuticals
Calendar
03/22Earnings Release
More about the company
Surperformance© ratings of Krka d.d. Novo Mesto
Trading Rating : Investor Rating :
More Ratings
Latest news on KRKA D.D. NOVO MESTO
07/18 KRKA D.D. NOVO MESTO : ex-dividend day for annual dividend
2016 KRKA D.D. NOVO MESTO : ex-dividend day for annual dividend
2015 KRKA D.D. NOVO MESTO : ex-dividend day for annual dividend
2015 KRKA D.D. NOVO MESTO : ex-dividend day for annual dividend
2014 KRKA D.D. NOVO MESTO : ex-dividend day for annual dividend
2013 KRKA D.D. NOVO MESTO : ex-dividend day for annual dividend
2012DJEU Sends Objections on Drug to Servier, Other Manufacturers
2012 KRKA D.D. NOVO MESTO : ex-dividend day for annual dividend
More news
Sector news : Generic Pharmaceuticals
03:12pDJSTOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
11:22a Germany's Merck in fresh bid to enter U.S. MS pill market
08:48aDJTEVA PHARMACEUTICAL INDUSTRIES : Generics Giant Cuts Staff by 25% -- WSJ
07:34aDJNOVARTIS : Oncology CEO Bruno Strigini to Retire
07:25aDJALNYLAM PHARMACEUTICALS : Stock Rises as FDA Lifts Study Hold
More sector news : Generic Pharmaceuticals
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 59,2 €
Spread / Average Target 8,6%
EPS Revisions
Managers
NameTitle
Jože Colaric President-Management Board & CEO
Jože Mermal Chairman-Supervisory Board
Brane Kastelec Director-Finance
Miran Kapš Director-Information Technology
Marko Lampret Director-Technical